About GoodCap Pharmaceuticals
GoodCap Pharmaceuticals is a company based in Toronto (Canada) founded in 2019 by Irie Selkirk and Darryl Hudson. It operates as a HealthTech. GoodCap Pharmaceuticals has raised $49.74 thousand across 1 funding round. The company has 49 employees as of May 27, 2025. GoodCap Pharmaceuticals offers products and services including GCAP001. GoodCap Pharmaceuticals operates in a competitive market with competitors including Escient Pharmaceuticals, Aclaris Therapeutics, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter Toronto, Canada
- Employees 49 as on 27 May, 2025
- Founders Irie Selkirk, Darryl Hudson
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Goodcap Pharmaceuticals
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$49.74 K (USD)
in 1 rounds
-
Latest Funding Round
$49.74 K (USD), Seed
Dec 04, 2024
-
Investors
Not available
-
Employee Count
49
as on May 27, 2025
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of GoodCap Pharmaceuticals
GoodCap Pharmaceuticals offers a comprehensive portfolio of products and services, including GCAP001.
Lead drug candidate targeting neuroinflammatory disorders like PTSD.
Funding Insights of GoodCap Pharmaceuticals
GoodCap Pharmaceuticals has successfully raised a total of $49.74K through 1 strategic funding round. The most recent funding activity was a Seed round of $49.74 thousand completed in December 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by GoodCap Pharmaceuticals
Investment portfolio details for GoodCap Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GoodCap Pharmaceuticals
Detailed financials for GoodCap Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Goodcap Pharmaceuticals Comparisons
Peer comparison for GoodCap Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GoodCap Pharmaceuticals
GoodCap Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Escient Pharmaceuticals, Aclaris Therapeutics, Nimbus Therapeutics, Alpine Immune Sciences and Septerna, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| Locked | Locked | Locked |
GPCR drug discovery platform is developed for multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for allergic and inflammatory diseases are developed.
|
Detailed competitors of GoodCap Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Goodcap Pharmaceuticals
Complete news archive for GoodCap Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GoodCap Pharmaceuticals
GoodCap Pharmaceuticals was founded in 2019 and raised its 1st funding round 5 years after it was founded.
GoodCap Pharmaceuticals is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
GoodCap Pharmaceuticals is a funded company, having raised a total of $49.74K across 1 funding round to date.
As of May 27, 2025, the latest employee count at GoodCap Pharmaceuticals is 49.
GoodCap Pharmaceuticals is engaged in the development of innovative medicines for neuroinflammatory disorders, with a primary focus on post-traumatic stress disorder (PTSD). The companys lead drug candidate, GCAP001, is designed to reduce inflammatory biomarkers associated with psychiatric and neurodegenerative conditions. Solutions are developed to address unmet needs in mental health and neurological care, targeting broad symptomology in affected populations. The organization operates within the healthcare and pharmaceutical sectors, aiming to provide safer and more effective therapeutic options.
GoodCap Pharmaceuticals's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
GoodCap Pharmaceuticals offers GCAP001.